Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $361.22 | 25 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $185.49 | 12 | $0 (2024) |
| The Medicines Company | $165.35 | 12 | $0 (2017) |
| PFIZER INC. | $10.38 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16.78 | 1 | Merck Sharp & Dohme LLC ($16.78) |
| 2017 | $344.44 | 24 | Merck Sharp & Dohme Corporation ($168.71) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/09/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/26/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/28/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/14/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/03/2017 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), DIFICID | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/28/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/20/2017 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), DIFICID | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/12/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $10.56 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/27/2017 | The Medicines Company | MINOCIN IV (Drug) | Food and Beverage | In-kind items and services | $12.40 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/26/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/17/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/10/2017 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/08/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/04/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/28/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $9.61 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/27/2017 | The Medicines Company | ORBACTIV (Drug), MINOCIN IV | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/13/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/24/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $20.14 | General |
| 03/23/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $17.83 | General |
| 03/17/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/09/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $17.31 | General |
| 02/24/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/27/2017 | The Medicines Company | MINOCIN IV (Drug), ORBACTIV | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/25/2017 | PFIZER INC. | PREVNAR - 13 (Biological) | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: VACCINES | ||||||
| 01/11/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 174 | 292 | $52,270 | $18,039 |
| 2022 | 5 | 126 | 246 | $47,361 | $16,329 |
| 2021 | 3 | 152 | 257 | $54,994 | $19,505 |
| 2020 | 4 | 151 | 290 | $57,274 | $20,485 |
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 59 | 133 | $20,216 | $7,702 | 38.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 34 | 35 | $14,770 | $4,530 | 30.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 19 | 38 | $3,154 | $1,398 | 44.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $4,018 | $1,355 | 33.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 14 | $3,038 | $1,243 | 40.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 23 | 42 | $4,578 | $1,028 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 16 | $2,496 | $782.93 | 31.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 55 | 161 | $24,472 | $8,562 | 35.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 29 | 29 | $12,238 | $4,283 | 35.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 20 | $5,740 | $2,020 | 35.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 21 | $3,276 | $1,059 | 32.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 11 | 15 | $1,635 | $405.88 | 24.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 76 | 180 | $27,360 | $9,687 | 35.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 41 | 41 | $17,302 | $6,215 | 35.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 35 | 36 | $10,332 | $3,603 | 34.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 81 | 209 | $31,768 | $11,593 | 36.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 44 | 45 | $18,990 | $6,920 | 36.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 15 | 15 | $4,305 | $1,578 | 36.6% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 11 | 21 | $2,211 | $394.40 | 17.8% |
About Dr. Haley Pritchard, MD
Dr. Haley Pritchard, MD is a Internal Medicine healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2013. The National Provider Identifier (NPI) number assigned to this provider is 1437492873.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Haley Pritchard, MD has received a total of $361.22 in payments from pharmaceutical and medical device companies, with $16.78 received in 2024. These payments were reported across 25 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($361.22).
As a Medicare-enrolled provider, Pritchard has provided services to 603 Medicare beneficiaries, totaling 1,085 services with total Medicare billing of $74,358. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Indianapolis, IN
- Active Since 04/04/2013
- Last Updated 03/04/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1437492873
Products in Payments
- MINOCIN IV (Drug) $83.50
- ORBACTIV (Drug) $81.85
- ZERBAXA (Drug) $71.06
- NOXAFIL (Drug) $28.58
- DIFICID (Drug) $16.78
- CUBICIN RF (Drug) $13.79
- PREVNAR - 13 (Biological) $10.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Indianapolis
Rafat Abonour, Md, MD
Internal Medicine — Payments: $833,709
David Batt, Md, MD
Internal Medicine — Payments: $682,018
Ashwin Ravichandran, Md, MD
Internal Medicine — Payments: $398,583
John Miller, Md, MD
Internal Medicine — Payments: $325,524
Naga Chalasani, Md, MD
Internal Medicine — Payments: $303,095
James Trippi, Md, MD
Internal Medicine — Payments: $280,481